Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

Table 1 Model parameters

	Panitumumab	Cetuximab	Range tested for sensitivity analysis	References
Survival outcomes (months)
Median PFS	4.1	4.4	95% CI	[7]
Median OS	10.4	10	95% CI	[7]
Cost
Drug acquisition	$4224^a	$1113^b	± 20%	[10]
Chemotherapy administration	$272	$330	± 20%	[12]
AEs management (per event)			± 20%
Skin rash	$5484			[13]
Hypomagnesemia	$7654			[13]
Hypokalemia	$1605			[15]
Infusion reaction	$2138 (Grade 1 and 2)			[14]
	$12,197 (≥ Grade 3)
Caregiver costs (per month)			± 20%
Progression-free	$1462			[17]
Progression	$2521			[17]
Best supportive care (per month)	$2754		± 20%	[16]
Utility
Progression-free state	0.745	0.74	± 20%	[18, 19]
Progressive state	0.65	0.65	± 20%	[20]

PFS progression-free survival, OS overall survival, BSC best supportive care
^aDrug acquisition cost for panitumumab of 400 mg/20 ml vial
^bDrug acquisition cost for cetuximab of 100 ml 2 mg/ml vial

ISSN: 1478-7547